Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis

Hayashi, Akira; Tanabe, Akiko; Kawabe, Sachiko; Hayashi, Mitsuko; Yuguchi, Hiroko; Yamashita, Yoshiki; Okuda, Kiyoji; Ohmichi, Masahide

doi:10.1186/1757-2215-5-31

Cited by 88 publications

(69 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, GnRH agonists induce cell apoptosis by increasing the expression of proapoptotic proteins (Bax, FasL) and decreasing antiapapthotic activity (Bcl-2) [10]. However, there is a concern regarding the possible influence of prolonged a-GnRH administration on endometrial receptivity, especially on the expression of implantation factors, such as avb3 integrin [6,12].…”

Section: Discussionmentioning

confidence: 99%

“…Another controversy of treatment with GnRH analogs is related to its negative effects associated with induced hypoestrogenemia: bone mineral density loss, hot flashes, and vaginal dryness [12]. Due to these side actions of the drug many patients "remember" the treatment with a-GnRH and do not always agree to repeat it, showing a decreased rate of adherence to the therapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Dienogest treatment after ovarian endometrioma removal in infertile women prior to IVF

Müller

Kogan

Yarmolinskaya

et al. 2017

Gynecological Endocrinology

View full text Add to dashboard Cite

Background: Severe forms of genital endometriosis are known to be associated with infertility and its subsequent treatment failure. Both gonadotropin-releasing hormone analogs (a-GnRH) and dienogest have been suggested as additional hormone therapy for patients with endometriomas. However, the result of hormonal suppression before an in vitro fertilization (IVF) cycle remains undetermined. Materials and methods: A prospective cohort study of 144 infertile women planning IVF after laparoscopic surgery of ovarian endometriomas was conducted at our department in 2012-2015. Patients were divided into three groups: group I (N ¼ 38) with dienogest course, group II (N ¼ 70) with a-GnRH group III (N ¼ 70) without any hormonal therapy within 6 months preceding IVF. Results: The study groups did not differ by removed endometriomas size and ovarian reserve indicators. The gonadotropin dose per Cycle was higher, while the number of retrieved oocytes was lower in group III patients (p < .001). In women with dienogest pretreatment, clinical pregnancy rate was 2.5 times (44.7% versus 16.7%, p ¼ .012) and delivery rate -three times higher (36.8% versus 11.1%, p ¼ .013) as compared with those from group III. Conclusions: The present study confirms the necessity of pre-cycle medical interventions in women with ovarian forms of endometriosis undergoing IVF. We suggest dienogest to be possibly more efficient treatment option for this kind of patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Dienogest treatment after ovarian endometrioma removal in infertile women prior to IVF

Müller

Kogan

Yarmolinskaya

et al. 2017

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

“…При лечении диеногестом до-казано снижение пролиферации, ароматазной ак-тивности и ангиогенеза, а также повышение апоп-тоза в очагах эндометриоза [20], что способствует уменьшению их размеров [21]. Наряду с этим на-блюдается повышение чувствительности и норма-лизация соотношения изоформ А/В прогестероно-вых рецепторов, уменьшение экспрессии эстроге-новых рецепторов (α и β) при эндометриозе яични-ков [22]. Перспектива дальнейшего развития кон-сервативного подхода к лечению ЭКЯ может опи-раться и на прогнозирование терапевтического эффекта в ответ на лечение диеногестом пациенток с овариальным эндометриозом по степени умень-шения эндометриомы, что предлагается M. Matsuura и соавт.…”

Section: таблица 1 базальный уровень гормонов у пациенток с эндометрunclassified

Results of conservative treatment of endometriomas

Клинышкова¹,

Perfilieva²,

Soveyko³

2015

Probl. reprod.

View full text Add to dashboard Cite

“…The amount of PRA was calculated by subtracting the relative amount of PRB from that of total PR. 15,36 The PR positive-status cutoff was set at 0.04, since this value agreed best with IHC results (see below).…”

Section: Rt-pcr Assaymentioning

confidence: 99%

Progesterone Receptor Isoform Analysis by Quantitative Real-Time Polymerase Chain Reaction in Formalin-Fixed, Paraffin-Embedded Canine Mammary Dysplasias and Tumors

et al. 2013

View full text Add to dashboard Cite

Cloning and sequencing of the progesterone receptor gene in dogs have revealed 2 isoforms, A and B, transcribed from a single gene. Distribution of isoforms A and B in canine mammary lesions has hitherto been investigated only by Western blot analysis. This study analyzed progesterone receptor and its isoforms in formalin-fixed, paraffin-embedded tissue samples from canine mammary lesions (4 dysplasias, 10 benign tumors, and 46 carcinomas) using 1-step SYBR Green quantitative real-time polymerase chain reaction (RT-qPCR). Progesterone receptor was expressed in 75% of dysplasias, all benign tumors, and 59% of carcinomas. Carcinomas, and particularly simple epithelial-type carcinomas, displayed the lowest levels of expression. A high rate of agreement was recorded between RT-qPCR and immunohistochemical labeling. Isoforms A and B were successfully amplified, with correlation coefficients of 0.99 and amplification efficiencies close to 2, and were expressed in all lesion types analyzed. Predominance of A over B expression was observed in carcinomas and complex adenomas. Low-grade tumors exhibited higher progesterone receptor messenger RNA (mRNA) levels, but no difference was observed in the expression of isoform A versus B. Analysis of progesterone receptor mRNA isoforms by RT-qPCR was successful in routinely formalin-fixed, paraffin-embedded tissue samples and enabled the distribution of isoforms A and B to be identified for the first time in dysplasias, benign tumors, and malignant tumors of the canine mammary gland. These findings will facilitate future research into the role of progesterone receptor isoforms in the progression of canine mammary tumors.

show abstract

Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis

Cited by 88 publications

References 47 publications

Dienogest treatment after ovarian endometrioma removal in infertile women prior to IVF

Dienogest treatment after ovarian endometrioma removal in infertile women prior to IVF

Results of conservative treatment of endometriomas

Progesterone Receptor Isoform Analysis by Quantitative Real-Time Polymerase Chain Reaction in Formalin-Fixed, Paraffin-Embedded Canine Mammary Dysplasias and Tumors

Contact Info

Product

Resources

About